Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (671-680 of 751) with videos related to

Pageof 76
Sort By:
American Heart Journal|May 9, 2022
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trialWarren J Cantor, Mary Tan, Otavio Berwanger, et al.
JAMA Cardiology|September 29, 2018
Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical TrialRenato D Lopes, Pedro G M de Barros E Silva, Isabella de Andrade Jesuíno, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Lancet (London, England)|June 17, 2014
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trialL Kristin Newby, Michael S Marber, Chiara Melloni, et al.
Journal of the American Heart Association|November 26, 2020
Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial FibrillationFrederik Dalgaard, Haolin Xu, Roland A Matsouaka, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
NEJM Evidence|May 26, 2026
Patient-Centered Evaluation of Anticoagulation in Atrial FibrillationSatoshi Shoji, Pishoy Gouda, Caroline A Falvey, et al.
Journal of Cardiac Failure|April 24, 2022
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF TrialBradi B Granger, Lisa A Kaltenbach, Gregg C Fonarow, et al.
Circulation. Heart Failure|December 10, 2019
Sex-Related Differences in Heart Failure With Preserved Ejection FractionPooja Dewan, Rasmus Rørth, Valeria Raparelli, et al.
Lancet (London, England)|October 6, 2012
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trialRenato D Lopes, Sana M Al-Khatib, Lars Wallentin, et al.
Pageof 76

Showing results (671-680 of 751) with videos related to

Sort By:
Pageof 76
American Heart Journal|May 9, 2022
Morphine and clinical outcomes in patients with ST segment elevation myocardial infarction treated with fibrinolytic and antiplatelet therapy: Insights from the TREAT trialWarren J Cantor, Mary Tan, Otavio Berwanger, et al.
JAMA Cardiology|September 29, 2018
Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical TrialRenato D Lopes, Pedro G M de Barros E Silva, Isabella de Andrade Jesuíno, et al.
Journal of Cardiac Failure|April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Eugene Braunwald, et al.
Lancet (London, England)|June 17, 2014
Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trialL Kristin Newby, Michael S Marber, Chiara Melloni, et al.
Journal of the American Heart Association|November 26, 2020
Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial FibrillationFrederik Dalgaard, Haolin Xu, Roland A Matsouaka, et al.
Journal of the American College of Cardiology|February 28, 2024
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMIDouglas L Mann, Johny Nicolas, Brian Claggett, et al.
NEJM Evidence|May 26, 2026
Patient-Centered Evaluation of Anticoagulation in Atrial FibrillationSatoshi Shoji, Pishoy Gouda, Caroline A Falvey, et al.
Journal of Cardiac Failure|April 24, 2022
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF TrialBradi B Granger, Lisa A Kaltenbach, Gregg C Fonarow, et al.
Circulation. Heart Failure|December 10, 2019
Sex-Related Differences in Heart Failure With Preserved Ejection FractionPooja Dewan, Rasmus Rørth, Valeria Raparelli, et al.
Lancet (London, England)|October 6, 2012
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trialRenato D Lopes, Sana M Al-Khatib, Lars Wallentin, et al.
Pageof 76